Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 3Withdrawn 2Terminated 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 77Stomach Neoplasms 14Neoplasms 8Neoplasm Metastasis 8HER2-positive Breast Cancer 4Esophageal Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Inflammatory Breast Neoplasms 3Breast Neoplasms, Male 3Triple Negative Breast Neoplasms 2Recurrence 2Ovarian Neoplasms 2Cardiotoxicity 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Solid Tumor 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1Meningeal Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Carboplatin 44Paclitaxel 43liposomal doxorubicin 23Topotecan 19Gemcitabine 18pembrolizumab 17Cyclophosphamide 17Bevacizumab 16Cisplatin 12niraparib 9olaparib 8fludarabine 7Taxes 7Docetaxel 7aldesleukin 6Nivolumab 6Doxorubicin 61-dodecylpyridoxal 6oregovomab 5fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5rucaparib 4durvalumab 4avelumab 4Surgical Procedures, Operative 4Melphalan 4Ipilimumab 4Interleukin-2 4Etoposide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Ovarian Neoplasms × Trastuzumab × Clear all
NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT00189579 2007-08-17

Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer

ARCAGY/ GINECO GROUP

Phase 2 Terminated
45 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡